Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) Financial statements for the period from 1 January 2013 to 31 March 2014

Transcription

1 Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) Financial statements for the period from 1 January 2013 to 31 March 2014

2 Independent auditors report to the members of Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) 1 Report on the Financial Statements We have audited the financial statements of Ranbaxy (Malaysia) Sdn. Bhd., which comprise the statement of financial position as at 31 March 2014, and the statements of profit or loss and other comprehensive income, changes in equity and cash flows for the period then ended, and a summary of significant accounting policies and other explanatory information, as set out on pages 5 to 39. Directors Responsibility for the Financial Statements The Directors of the Company are responsible for the preparation of financial statements so as to give a true and fair view in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act, 1965 in Malaysia. The Directors are also responsible for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. Auditors Responsibility Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with approved standards on auditing in Malaysia. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgement, including the assessment of risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity s preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Directors, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3 2 Company No K Opinion In our opinion, the financial statements give a true and fair view of the financial position of the Company as of 31 March 2014, and of its financial performance and cash flows for the period then ended in accordance with Malaysian Financial Reporting Standards, International Financial Reporitng Standards and the requirements of the Companies Act, 1965 in Malaysia. Report on Other Legal and Regulatory Requirements In accordance with the requirements of the Companies Act, 1965 in Malaysia, we also report that in our opinion the accounting and other records and the registers required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act. Other Matters This report is made solely to the members of the Company, as a body, in accordance with Section 174 of the Companies Act, 1965 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report. KPMG Firm Number: AF 0758 Chartered Accountants Mok Wan Kong Approval Number: 2877/12/14(J) Chartered Accountant Date: 20 May 2014

4 3 Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) Directors report for the period ended 31 March 2014 The Directors hereby submit their report and the audited financial statements of the Company for the period ended from 1 January 2013 to 31 March Principal activities The Company is principally engaged in manufacturing and distributing of pharmaceutical products. There has been no significant change in the nature of these activities during the financial period. Change of financial year end During the financial period, the Company changed its financial year end from 31 December to 31 March to conform to group financial year end. Results RM 000 Loss for the period 22,906 INR 000 Loss for the period 426,555 Reserves and provisions There were no material transfers to or from reserves and provisions during the financial period under review except as disclosed in the financial statements. Dividends Since the end of the previous financial year, the Company paid a first and final tax exempt dividend of 10 sen per ordinary share of RM1.00 each totalling RM800,000 (INR 14,869,888) in respect of the financial year ended 31 December 2012 on 27 June The Directors do not recommend any other dividend to be paid for the financial period.

5 Company No K 4 Directors of the Company Directors who served since the date of the last report are: Santha Bhaskara Menon Dato Abdullah bin Mohd Yusof Jeyabalan A/L V. Thangarajah Ashwani Kumar Malhotra Rajiv Gulati Indrajit Banerjee Alok Shubkar Kapoor (appointed on 31 October 2013) Rajeev Sharma (resigned with effect from 10 April 2014) Directors interests The interests and deemed interests in the ordinary shares of the Company and of its related corporations of those who were Directors at financial year end (including the interests of the spouses or children of the Directors who themselves are not Directors of the Company) as recorded in the Register of Directors Shareholdings are as follows: Number of ordinary shares of RM1 each At Bought (Sold) At Interest in the holding company Santha Bhaskara Menon -own 1, ,046 None of the other Directors holding office at 31 March 2014 had any interest in the ordinary shares of the Company and of its related corporations during the financial period. Directors benefits Since the end of the previous financial year, no Director of the Company has received nor become entitled to receive any benefit (other than a benefit included in the aggregate amount of emoluments received or due and receivable by Directors as shown in the financial statements or the fixed salary of a full time employee of the Company or of related corporations) by reason of a contract made by the Company or a related corporation with the Director or with a firm of which the Director is a member, or with a company in which the Director has a substantial financial interest. There were no arrangements during and at the end of the financial period which had the object of enabling Directors of the Company to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

6 Company No K 5 Issue of shares and debentures There were no changes in the authorised, issued and paid-up share capital of the Company during the financial period. There were no debentures issued during the financial period. Options granted over unissued shares and debentures No options were granted to any person to take up unissued shares or debentures of the Company during the financial period. Other statutory information Before the financial statements of the Company were made out, the Directors took reasonable steps to ascertain that: i) all known bad debts have been written off and adequate provision made for doubtful debts, and ii) any current assets which were unlikely to be realised in the ordinary course of business have been written down to an amount which they might be expected so to realise. At the date of this report, the Directors are not aware of any circumstances: i) that would render the amount written off for bad debts, or the amount of the provision for doubtful debts in the Company inadequate to any substantial extent, or ii) iii) iv) that would render the value attributed to the current assets in the Company s financial statements misleading, or which have arisen which render adherence to the existing method of valuation of assets or liabilities of the Company misleading or inappropriate, or not otherwise dealt with in this report or in the financial statements, that would render any amount stated in the financial statements of the Company misleading. At the date of this report, there does not exist: i) any charge on the assets of the Company that has arisen since the end of the financial year and which secures the liabilities of any other person, or ii) any contingent liability in respect of the Company that has arisen since the end of the financial year.

7 Company No K 6 Other statutory information (continued) No contingent liability or other liability of the Company has become enforceable, or is likely to become enforceable within the period of twelve months after the end of the financial period which, in the opinion of the Directors, will or may substantially affect the ability of the Company to meet its obligations as and when they fall due. In the opinion of the Directors, the financial performance of the Company for the financial period ended 31 March 2014 have not been substantially affected by any item, transaction or event of a material and unusual nature nor has any such item, transaction or event occurred in the interval between the end of that financial year and the date of this report. Significant events subsequent to reporting date The significant event subsequent to reporting date is as disclosed in Note 21 to the financial statements. Auditors The auditors, Messrs KPMG, have indicated their willingness to accept re-appointment. Signed on behalf of the Board of Directors in accordance with a resolution of the Directors:. Dato Abdullah bin Mohd Yusof Jeyabalan A/L V. Thangarajah Date: 20 May 2014

8 Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) 7 Statement of financial position as at 31 March 2014 Note RM 000 RM 000 Asset Property, plant and equipment 3 38,094 33,872 Total non-current asset 38,094 33,872 Inventories 4 30,671 27,585 Trade and other receivables 5 43,974 59,014 Tax recoverable Cash and bank balances Total current assets 75,759 87,098 Total assets 113, ,970 Equity Share capital 6 8,000 8,000 Share premium Retained earnings 7 48,795 72,501 Total equity 57,095 80,801 Liability Deferred tax liabilities 8-1,311 Total non-current liability - 1,311 Bank borrowings 9 26,142 13,175 Provisions Trade and other payables 11 29,957 25,538 Total current liabilities 56,758 38,858 Total liabilities 56,758 40,169 Total equity and liabilities 113, ,970 Asset Note INR'000 INR'000 Property, plant and equipment 3 695, ,939 Total non-current asset 695, ,939 Inventories (3,086) 4 559, ,470 Trade and other receivables 15, ,447 1,055,707 Tax recoverable (91) 12,831 6,655 Cash and bank balances 7,498 2,272 Total current assets 1,382,458 1,558,104 Total assets 2,077,604 2,164,043 Share capital 6 145, ,113 Share premium 5,474 5,367 Retained earnings 7 890,426 1,296,977 1,041,886 1,445,456 Liability Deferred tax liabilities (1,311) 8-23,453

9 Total non-current liability - 23,453 Bank borrowings 9 477, ,689 Provisions ,020 2,594 Trade and other payables 4, , ,852 Total current liabilities 1,035, ,134 Total liabilities 1,035, ,587 Total equity and liabilities 2,077,604 2,164,043 8 The notes on pages 9 to 39 are an integral part of these financial statements.

10 Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) 9 Statement of profit or loss and other comprehensive income for the period from 1 January 2013 to 31 March 2014 Note to RM to RM 000 Revenue 76,378 92,991 Cost of sales (71,870) (61,640) Gross profit 4,508 31,351 Other operating income 2, Distribution costs (17,283) (13,983) Administrative expenses (8,150) (7,945) Other operating expenses (3,767) (72) Result from operating activities (22,515) 9,713 Finance costs (2,124) (1,138) (Loss)/Profit before tax 12 (24,639) 8,575 Tax credit/(expense) 14 1,733 (1,755) (Loss)/Profit and total comprehensive (expense)/income for the period/year (22,906) 6, INR '000 INR '000 Revenue 1,422,308 1,608,841 Cost of sales (1,338,360) (1,066,436) Gross profit 83, ,405 Other operating income 40,540 6,263 Distribution costs (321,839) (241,920) Administrative expenses (151,768) (137,457) Other operating expenses (70,156) (1,246) Result from operating activities (419,276) 168,045 Finance costs (39,547) (19,689) Profit before tax 12 (458,823) 148,356 Tax expense 14 32,277 (30,363) Profit for the year/total comprehensive income for the year (426,555) 117,993 ===== =====

11 10 The notes on pages 9 to 39 are an integral part of these financial statements. Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) Statement of changes in equity for the period from 1 January 2013 to 31 March 2014 Note Non distributable Distributable Share Share Retained capital premium earnings Total RM 000 RM 000 RM 000 RM 000 At 1 January , ,481 74,781 Profit and total comprehensive income for the year - - 6,820 6,820 Dividends (800) (800) At 31 December 2012/ 1 January , ,501 80,801 Loss and total comprehensive expense for the period - - (22,906) (22,906) Dividends (800) (800) At 31 March , ,795 57,095 Note 6 Note 7 Share Share Retained Note capital premium earnings Total INR '000 INR '000 INR '000 INR '000 At 1 January ,003 5,025 1,113,585 1,252,613 Profit for the year/ Total comprehensive income for the year 117, ,993 Dividends 15 (13,841) (13,841) Translation of Exchange Rates 9, ,240 88,691 At 31 December 2012/ 1-Jan ,113 5,367 1,296,977 1,445,456 1-Jan-13 Profit for the year/ Total comprehensive income for the year (426,555) (426,555) Dividends 15 (14,898) (14,898) Translation of Exchange Rates 2, ,895 37,876 At 31 March ,985 5, ,419 1,041,879 The notes on pages 9 to 39 are an integral part of these financial statements.

12 Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) 11 Statement of cash flows for the period from 1 January 2013 to 31 March to to RM 000 RM 000 Cash flows from operating activities (Loss)/Profit before tax (24,639) 8,575 Adjustments for: Depreciation of property, plant and equipment 3,918 2,376 Impairment loss on trade receivables Interest expense 2,124 1,138 Loss/(Gain) on disposal of property, plant and equipment 18 (27) Property, plant and equipment written off 18 1 Unrealised loss/(gain) on foreign exchange 830 (285) Operating (loss)/profit before changes in working capital (17,223) 11,848 Change in inventories (3,693) 3,365 Change in trade and other receivables 15,404 (4,074) Change in trade and other payables 2,717 1,579 Change in provisions Cash (used in)/generated from` operations (2,281) 12,788 Taxes paid 90 (1,667) Interest paid (2,124) (1,138) Net cash (used in)/generated from operating activities (4,315) 9,983 Cash flows from investing activities Purchase of property, plant and equipment (7,574) (11,156) Proceeds from disposal of property, plant and equipment 6 27 Net cash used in investing activities (7,568) (11,129) Cash flows from financing activities Dividends paid (800) (800) Drawdown of bank borrowings 12,967 1,607 Net cash generated from financing activities 12, Net increase/(decrease) in cash and bank balances 284 (339) Cash and bank balances at 1 January Cash and bank balances at 31 March/December INR '000 INR '000 Cash flows from operating activities Profit before tax (458,827) 148,356 Adjustments for: Allowance for doubtful debts 9,464 1,211 Depreciation of property, plant and equipment 72,968 41,107 Impairment loss/(reversal of impairment loss) on property, plant and equipment - -

13 Interest expense 39,547 19, (Gain)/Loss on disposal of property, plant and equipment 335 (467) Property, plant and equipment written off Unrealised loss/(gain) on foreign exchange 15,464 (4,931) Forex on translation (79) 331 Operating (loss)/profit before changes in working capital (320,793) 205,314 Change in inventories (68,771) 58,218 Change in trade and other receivables 286,846 (70,484) Change in trade and other payables 50,596 27,318 Change in provisions 9,571 1,211 Cash generated (used in)/from operations (42,551) 221,577 Taxes refund/(paid) 1,676 (28,841) Interest paid (39,547) (19,689) Net cash generated from/(used in) operating activities (80,421) 173, Cash flows from investing activities Purchase of property, plant and equipment (141,043) (193,010) Proceeds from disposal of property, plant and equipment Net cash used in investing activities (140,927) (192,543) Cash flows from financing activities Dividends paid (14,898) (13,841) Drawndown of bank borrowings 241,476 27,803 Repayment of bank borrowings - - Net cash (used in)/generated from financing activities 226,578 13, Net increase/(decrease) in cash and bank balances 5,230 (5,534) Cash and bank balances at 1 January 2,272 7,806 Cash and bank balances at 31 December 7,502 2,272 ===== =====

14 The notes on pages 9 to 39 are an integral part of these financial statements. 13 Ranbaxy (Malaysia) Sdn. Bhd. (Company No K) (Incorporated in Malaysia) Notes to the financial statements Ranbaxy (Malaysia) Sdn. Bhd. is a private limited liability company, incorporated and domiciled in Malaysia. The addresses of the principal place of business and registered office of the Company are as follows: Principal place of business Peti #8, Wisma Selangor Dredging 5 th Floor, South Block 142-A, Jalan Ampang Kuala Lumpur Registered office Lot 6.05, Level 6, KPMG Tower 8 First Avenue, Bandar Utama Petaling Jaya Selangor Darul Ehsan The Company is principally engaged in manufacturing and distributing of pharmaceutical products. The immediate holding company is Ranbaxy Laboratories Limited, a company incorporated in India and listed in Mumbai Stock Exchange, National Stock Exchange of India and Luxembourg Stock Exchange. The ultimate holding company is Daiichi Sankyo Company Limited, a corporation incorporated in Japan and listed in Tokyo Stock Exchange, Osaka Securities Exchange and Nagoya Stock Exchange. The financial statements were authorised for issue by the Board of Directors on 20 May Basis of preparation (a) Statement of compliance The financial statements of the Company have been prepared in accordance with Malaysian Financial Reporting Standards ( MFRS ), International Financial Reporting Standards and the requirements of the Companies Act, 1965 in Malaysia. The following are accounting standards, amendments and interpretations of the MFRS framework that have been issued by the Malaysian Accounting Standards Board ( MASB ) but have not been adopted by the Company. Company No K 1. Basis of preparation (continued) (a) Statement of compliance (continued) MFRSs, Interpretations and amendments effective for annual periods beginning on or after 1 January 2014 Amendments to MFRS 10, Consolidated Financial Statements: Investment Entities. Amendments to MFRS 12, Disclosure of Interest in Other Entities : Investment Entities Amendments to MFRS 127, Separate Financial Statements (2011) : Investment Entities Amendments to MFRS 132, Financial Instruments: Presentation Offsetting Financial Assets and Financial Liabilities

15 Amendments to MFRS 136, Impairment of Assets Recoverable Amount Disclosures for Non-Financial Assets Amendments to MFRS 139, Financial Instruments: Recognition and Measurement Novation of Derivatives and Continuation of Hedge Accounting IC Interpretation 21, Levies MFRS, Interpretations and amendments effective for annual periods beginning on or after 1 July 2014 Amendments to MFRS 1, First-Time Adoption of Malaysian Financial Reporting Standards (Annual Improvements Cycle) Amendments to MFRS 2, Share-based Payments (Annual Improvements Cycle) Amendments to MFRS 3, Business Combinations (Annual Improvements Cycle and Cycle) Amendments to MFRS 8, Operating Segments (Annual Improvements cycle) Amendments to MFRS 13, Fair Value Measurement (Annual Improvements Cycle and Cycle) Amendments to MFRS 116, Property, Plant and Equipment (Annual Improvements Cycle) Amendments to MFRS 119, Employee Benefits Defined Benefit Plans: Employee Contribution Amendments to MFRS 124, Related Party Disclosures (Annual Improvements Cycle) Amendments to MFRS 138, Intangible Assets (Annual Improvements Cycle) Amendments to MFRS 140, Investment Property (Annual Improvements Cycle) 14 Company No K 1. Basis of preparation (continued) (a) Statement of compliance (continued) MFRS, Interpretations and amendments effective for a date yet to be confirmed MFRS 9, Financial Instruments (2009) MFRS 9, Financial Instruments (2010) MFRS 9, Financial Instruments-Hedge Accounting and amendments to MFRS 9, MFRS 7 and MFRS 139 Amendments to MFRS 7, Financial Instruments: Disclosures Mandatory Effective Date of MFRS 9 and Transition Disclosures The Company plans to apply the abovementioned accounting standards, amendments and interpretations: From the annual period beginning on 1 April 2014 for those accounting standards, amendments or interpretations that are effective for annual periods beginning on or after 1 January 2014, except for MFRS 10, 12, 127 and IC Interpretation 21 which are not applicable to the Company. From the annual period beginning on 1 April 2015 for those accounting standards, amendments or interpretations that are effective for annual periods beginning on or after 1 July 2014, except for MFRS 1, 2, 3, 8, 119, 138 and 140 which are not applicable to the Company. The initial application of the accounting standards, amendments and interpretations are not expected to have any material financial impacts to the current period and prior period financial statements of the company except as mentioned below:

16 MFRS 9, Financial Instruments 15 MFRS 9 replaces the guidance in MFRS 139, Financial Instrument: Recognition and Measurement on the classification and measurement of financial assets. Upon adoption of MFRS 9, financial assets will be measured at either fair value or amortised cost. The adoption of MFRS 9 will result in a change in accounting policy. The Company is currently assessing the financial impact of adopting MFRS 9. (b) Basis of measurement The financial statements of the Company have been prepared on the historical cost basis, except as disclosed in Note 2.

17 Company No K Basis of preparation (continued) (c) Functional and presentation currency These financial statements are presented in Ringgit Malaysia (RM), which is the Company s functional currency. All financial information is presented in RM and has been rounded to the nearest thousand, unless otherwise stated. (d) Use of estimates and judgements The preparation of financial statements in conformity with MFRSs requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected. There are no significant areas of estimation uncertainty and critical judgements in applying accounting policies that have significant effect on the amounts recognised in the financial statements other than those disclosed in Note 10, Provisions. 2. Significant accounting policies The accounting policies set out below have been applied consistently to the period presented in these financial statements, unless otherwise stated. (a) Foreign currency Foreign currency transactions Transactions in foreign currencies are translated to the functional currency of the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the exchange rate at that date. Non-monetary assets and liabilities denominated in foreign currencies are not retranslated at the end of the reporting date except for those that are measured at fair value are retranslated to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising on retranslation are recognised in profit or loss.

18 Company No K Significant accounting policies (continued) (b) Property, plant and equipment (i) Recognition and measurement Items of property, plant and equipment are stated at cost less any accumulated depreciation and any accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset and any other costs directly attributable to bringing the asset to working condition for its intended use, and the costs of dismantling and removing the items and restoring the site on which they are located. The cost of self-constructed assets includes the cost of materials and direct labour. Purchased software that is integral to the functionality of the related equipment is capitalised as part of that equipment. When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. The gain or loss on disposal of an item of property, plant and equipment is determined by comparing proceeds from disposal with the carrying amount of property, plant and equipment and is recognised net within other income and other expenses respectively in profit or loss. (ii) Subsequent costs The cost of replacing a component of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company, and its cost can be measured reliably. The carrying amount of the replaced part is derecognised to profit or loss. The costs of the day-to-day servicing of property, plant and equipment are recognised in profit or loss as incurred. (iii) Depreciation Depreciation is based on the cost of an asset less its residual value. Significant components of individual assets are assessed, and if a component has a useful life that is different from the remainder of that asset, then that component are depreciated separately. Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Capital work-in-progress are not depreciated until the assets are ready for their intended use.

19 Company No K Significant accounting policies (continued) (b) Property, plant and equipment (continued) (iii) Depreciation (continued) The estimated useful lives for the current and comparative periods are as follows: Leasehold land Amortised over the lease term of 60 years Factory building Amortised over the lease term of 60 years Office equipment and renovations 3 10 years Furniture and fittings 10 years Motor vehicles 6.7 years Plant and machinery 10 years Spare parts, stand-by equipment and servicing equipment. 4 years Depreciation methods, useful lives and residual values are reviewed at the end of the reporting period, and adjusted as appropriate. (c) Leased assets Operating lease Lease, where the Company does not assume substantially, all the risks and rewards of the ownership are classified as operating lease and the leased assets are not recognised in the statement of financial position of the Company. Payments made under operating leases are recognised in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognised in profit or loss as an integral part of the total lease expense, over the term of the lease. Leasehold land which in substance is an operating lease is classified as prepaid lease payments. (d) Inventories Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on the weighted average cost formula, and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. The cost of raw materials and indirect materials comprises the original purchase price plus incidentals in bringing these inventories to their present location and condition. In the case of work-in-progress and finished goods, cost includes an appropriate share of production overheads based on normal operating capacity.

20 Company No K Significant accounting policies (continued) (d) Inventories (continued) Net realisable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and estimated costs necessary to make the sale. (e) Financial instruments (i) Initial recognition and measurement A financial asset or a financial liability is recognised in the statement of financial position when, and only when, the Company becomes a party to the contractual provisions of the instrument. A financial instrument is recognised initially, at its fair value plus, in the case of a financial instrument not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial instrument. An embedded derivative is recognised separately from the host contract and accounted for as a derivative if, and only if, it is not closely related to the economic characteristics and risks of the host contract and the host contract is not categorised at fair value through profit or loss. The host contract, in the event an embedded derivative is recognised separately, is accounted for in accordance with policy applicable to the nature of the host contract. (ii) Financial instrument categories and subsequent measurement The Company categorise financial instruments as follows: Financial assets Loans and receivables Loans and receivables category comprises debt instruments that are not quoted in an active market, trade and other receivables and cash and cash equivalents. Financial assets categorised as loan and receivables are subsequently measured at amortised cost using effective interest method. All financial assets are subject to review for impairment (see note 2(g)(i)).

21 Company No K Significant accounting policies (continued) (e) Financial instruments (continued) (ii) Financial instrument categories and subsequent measurement (continued) Financial liabilities All financial liabilities are subsequently measured at amortised cost other than those categorised as fair value through profit or loss. Fair value through profit or loss category comprises financial liabilities that are held for trading, derivatives (except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument) or financial liabilities that are specifically designated into this category upon initial recognition. Derivatives that are linked to and must be settled by delivery of unquoted equity instruments whose fair values cannot be reliably measured are measured at cost. Other financial liabilities including trade and other payables and bank borrowings, categorised as fair value through profit or loss are subsequently measured at their fair value with the gain or loss recognised in profit or loss. (iii) Derecognition A financial asset or part of it is derecognised when, and only when the contractual rights to the cash flows from the financial asset expire or the financial asset is transferred to another party without retaining control or substantially all risks and rewards of the asset. On derecognition of a financial asset, the difference between the carrying amount and the sum of the consideration received (including any new asset obtained less any new liability assumed) and any cumulative gain or loss that had been recognised in equity is recognised in profit or loss. A financial liability or a part of it is derecognised when, and only when, the obligation specified in the contract is discharged or cancelled or expires. On derecognition of a financial liability, the difference between the carrying amount of the financial liability extinguished or transferred to another party and the consideration paid, including any noncash assets transferred or liabilities assumed, is recognised in profit or loss. (f) Cash and bank balances Cash and bank balances consist of cash on hand and bank balances.

22 Company No K Significant accounting policies (continued) (g) Impairment (i) Financial assets All financial assets are assessed at each reporting date whether there is any objective evidence of impairment as a result of one or more events having an impact on the estimated future cash flows of the asset. Losses expected as a result of future events, no matter how likely, are not recognised. For an equity instrument, a significant or prolonged decline in the fair value below its cost is an objective evidence of impairment. If any such objective evidence exists, then the financial assets recoverable amount is estimated. An impairment loss in respect of loans and receivables and held-to-maturity investments is recognised in profit or loss and is measured as the difference between the asset s carrying amount and the present value of estimated future cash flows discounted at the asset s original effective interest rate. The carrying amount of the asset is reduced through the use of an allowance account. If, in a subsequent period, the fair value of a debt instrument increases and the increase can be objectively related to an event occurring after the impairment loss was recognised in profit or loss, the impairment loss is reversed, to the extent that the asset s carrying amount does not exceed what the carrying amount would have been had the impairment not been recognised at the date the impairment is reversed. The amount of the reversal is recognised in profit or loss. (ii) Other assets The carrying amounts of other assets (except for inventories) are reviewed at the end of each reporting period to determine whether there is any indication of impairment. If any such indication exists, then the asset s recoverable amount is estimated. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or cash-generating units. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash generating unit.

23 Company No K Significant accounting policies (continued) (g) Impairment (continued) (ii) Other assets (continued) An impairment loss is recognised if the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in profit or loss. Impairment losses recognised in prior periods are assessed at the end of each reporting period for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount since the last impairment loss was recognised. An impairment loss is reversed only to the extent that the asset s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. Reversals of impairment losses are credited to profit or loss in the year in which the reversals are recognised. (h) Provisions A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance cost. Contingent liabilities Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote. Possible obligations, whose existence will only be confirmed by the occurrence or non-occurrence of one or more future events, are also disclosed as contingent liabilities unless the probability of outflow of economic benefits is remote.

24 Company No K Significant accounting policies (continued) (i) Employee benefits (i) Short-term employee benefits Short-term employee benefit obligations in respect of salaries, annual bonuses, paid annual leave and sick leave are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. (ii) State plans The Company s contributions to the statutory pension funds are charged to profit or loss in the period to which they relate. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in future is available. (j) Equity instruments Instruments classified as equity are measured at cost on initial recognition and are not remeasured subsequently. (i) Issue expenses Costs directly attributable to the issue of instruments classified as equity are recognised as a deduction from equity. (ii) Ordinary shares Ordinary shares are classified as equity.

25 Company No K Significant accounting policies (continued) (k) Revenue recognition Goods sold Revenue from the sale of goods in the course of ordinary activities is measured at fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. Revenue is recognised when persuasive evidence exists, usually in the form of an executed sales agreement, that the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, and there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. If it is probable that discounts will be granted and the amount can be measured reliably, then the discount is recognised as a reduction of revenue as the sales are recognised. (l) Borrowing costs Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss using the effective interest method. Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets. The capitalisation of borrowing costs as part of the cost of a qualifying asset commences when expenditure for the asset is being incurred, borrowing costs are being incurred and activities that are necessary to prepare the asset for its intended use or sale are in progress. Capitalisation of borrowing costs is suspended or ceases when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are interrupted or completed. Company No K 2. Significant accounting policies (continued) (m) Income tax Income tax expense comprises current and deferred tax. Income tax expense is recognised in profit or loss except to the extent that it relates to a business combination or items recognised directly in equity or other comprehensive income. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous financial years.

26 25 Deferred tax is recognised using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities in the statement of financial position and their tax bases. Deferred tax is not recognised for the temporary differences that affects neither accounting nor taxable profit nor loss. Deferred tax is measured at the tax rates that are expected to apply to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the end of the reporting period. The amount of deferred tax recognised is measured based on the expected manner of realisation or settlement of the carrying amount of the assets and liabilities, using tax rates enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are not discounted. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entitites, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously. A deferred tax asset is recognised to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax assets are reviewed at the end of each reporting period and are reduced to the extent that it is no longer probable that the related tax benefit will be realised. A tax incentive that is not a tax base of an asset is recognised as a reduction of tax expense in profit or loss as and when it is granted and claimed. Any unutilised portion of the tax incentive is recognised as a deferred tax asset to the extent that it is probable that future taxable profits will be available against which the unutilised tax incentive can be utilised.

27 Company No K Significant accounting policies (continued) (n) Fair value measurements From 1 January 2013, the Company adopted MFRS 13, Fair Value Measurement which prescribed that fair value of an asset or a liability, except for share-based payment and lease transactions, is determined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The measurement assumes that the transaction to sell the asset or transfer the liability takes place either in the principal market or in the absence of a principal market, in the most advantageous market. For non-financial asset, the fair value measurement takes into account a market participant s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. In accordance with the transitional provision of MFRS 13, the Company applied the new fair value measurement guidance prospectively, and has not provided any comparative fair value information for new disclosures. The adoption of MFRS 13 has not significantly affected the measurements of the Company s assets or liabilities.

28 Company No K Property, plant and equipment Spare parts, standby equipment and servicing Leasehold Land Factory building Office equipment and renovations Furniture and fittings Motor vehicles Plant and machinery equipment Capital work in progress Total RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 Cost At 1 January ,445 2, , ,114 Additions ,116 11,156 Transfers - 6, ,736 - (10,115) - Disposal (429) - - (429) Written off - - (20) (20) At 31 December 2012/ 1 January ,168 2, ,911-1,996 49,821 Additions ,574 7,574 Written off Disposals (174) (20) (373) (165) (547) (185) Transfers ,265 - (8,187) - Reclassification from Inventories At 31 March ,316 3, , ,383 57,271

29 Company No K Property, plant and equipment (continued) Spare parts, standby equipment and servicing Leasehold land Factory building Office equipment and renovations Furniture and fittings Motor vehicles Plant and machinery equipment Capital work in progress Total RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 RM 000 Accumulated depreciation At 1 January 2012 Accumulated depreciation 95 2,286 1, , ,733 Accumulated impairment loss ,286 1, , ,021 Depreciation for the year , ,376 Disposal (429) - - (429) Written off - - (19) (19) At 31 December 2012/ 1 January 2013 Accumulated depreciation 98 2,612 2, , ,661 Accumulated impairment loss ,612 2, , ,949 Depreciation for the period , ,918 Disposal - - (20) - - (141) - - (161) Written off - - (167) - - (362) - - (529) At 31 March 2014 Accumulated depreciation 103 3,147 2, , ,889 Accumulated impairment loss Carrying amounts 103 3,147 2, , ,177 At 1 January , , ,093 At 31 December 2012/ 1 January , ,043-1,996 33,872 At 31 March , , ,383 38,094

30 Company No K 29 Office equipment Furniture Spare parts, standby equipment and Capital Leasehold Factory and and Motor Plant and servicing work-in- Land building renovations fittings vehicles machinery equipment progress Total Cost INR '000 INR '000 INR '000 INR '000 INR '000 INR '000 INR '000 INR '000 INR '000 At 1 January , ,710 40,905 5,879 1, ,174 16, ,176 Additions , ,837 Transfer from/(to) - - 8,183 3,339-47,336 (175,000) (116,142) Disposals (7,422) - (7,422) Written off - - (346) (346) Forex translation ,873 3, ,672 1, ,166 At 31 December 2012/1 January , ,565 51,843 10,000 1, ,968 35, ,269 Additions , ,035 Transfer from/(to) 10,459 3, ,291 (152,456) (2,758) Disposals - (3,066) (3,066) Written off - (3,242) - (6,944) (10,186) Reclassification from Inventories 11,322 11,322 Forex translation 81 10, ,353 (227) ,489 At 31 March , ,226 59,590 14,069 1, ,602 11,095 25,232 1,045,105 Office equipment Furniture standby equipment and Leasehold Factory and and Motor Plant and servicing Capital workin- land building renovations fittings vehicles machinery equipment progress Total INR INR INR Cost INR '000 INR '000 INR '000 INR '000 '000 INR '000 INR '000 '000 '000 Property, plant and equipment (continued) Accumulated depreciation and impairment loss At 1 January 2012 Accumulated depreciation 1,591 38,291 30,704 2,647 1, , Accumulated impairment loss 30,821 -

31 30 1,591 38,291 2,680 1, , ,858 Depreciation for the year 52 5,640 5, , ,107 Impairment loss Disposals - (7,422) - - (7,422) Written off (329) (329) Forex translation 110 2,795 2, ,664 17,099 At 31 December 2012/1 January 2013 Accumulated depreciation 1,753 46,726 37,621 3,506 1, , ,161 Accumulated impairment loss , ,152 1,753 46,726 37,746 3,542 1, , ,313 Depreciation for the year 88 9,963 7,794 1,488-53, ,945 Impairment loss Disposals (372) - (2,629) - - (3,002) Written off - (3,107) - (6,741) - - (9,849) Forex translation ,037 (5) 4,538 At 31 March 2014 Accumulated depreciation 1,874 57,427 42,603 5,035 1, , ,673 Accumulated impairment loss ,109-5,273 1,874 57,427 42,731 5,072 1, , ,947 Carrying amounts At 1 January , ,419 10,084 3, ,755 16, ,318 At 31 December 2012/1 January , ,839 14,097 6, ,549 35, ,939 At 31 March , ,799 16,859 8, ,146 10,858 25, , Property, plant and equipment (continued) 3.1 Land 4. Inventories Leasehold land comprises land with an unexpired period of more than 50 years RM 000 RM 000 Raw materials 9,010 8,323 Work-in-progress 565 1,927 Finished goods 14,992 10,733 Packaging materials 2,917 2,542 Supplies and consumables 3,187 4,060 30,671 27,585